Dare to innovate with us

Eric DESSERTENNE (PharmD) is the Founder & CEO of Xderma. He is the former CEO of Biocorp, a connected drug delivery device company listed on Euronext (ALCOR) and acquired by Novo Nordisk. With prior experience in strategy consulting at LEK and leadership roles at Servier, Eric brings extensive expertise in MedTech innovation, IPO processes, and strategic partnerships across the life sciences sector.

Paul BRAVETTI (PharmD, HEC graduate) brings nearly 15 years of experience in the pharmaceutical industry (Roche, Servier, Takeda), where he successfully led the launch of innovative therapies across Europe and Asia. Since 2020, under his leadership, Brenus has raised €30M to launch a clinical trial and established partnerships with international centers of excellence.

Jacques GARDETTE is a serial entrepreneur in helthcare & digital Health. He has founded 10+ companies in his career, with successful exits: 6 of these being sold to large lifescience companies such as Bard, Baxter or Nipro Healthcare in various areas from dialysis, drug delivery devices or cardiac valves. Former funder and principal shareholder of Biocorp, pioneer in innovative medicale devices, listed on Euronext Paris, now sold to Novo Nordisk for 154M€.

‍

Jacques GARDETTE is a serial entrepreneur in helthcare & digital Health. He has founded 10+ companies in his career, with successful exits: 6 of these being sold to large lifescience companies such as Bard, Baxter or Nipro Healthcare in various areas from dialysis, drug delivery devices or cardiac valves. Former funder and principal shareholder of Biocorp, pioneer in innovative medicale devices, listed on Euronext Paris, now sold to Novo Nordisk for 154M€.

Diala EZZEDINE (PhD) is an US-based biotech executive with 20+ years of leadership in company building, business development, and strategic growth. Currently Head of Business & Corporate Development at Magnet Biomedicine (molecular glue therapeutics) and Independent Director at Epigene Labs (AI-driven biotech). Former EVP & CBO at X-Chem Pharmaceuticals (led strategic partnerships and acquisition by PPD) and founder of Xios Therapeutics (immuno-oncology). Ph.D. in Genetics from Harvard Medical School.

Camilla SYLVEST (MSc, MBA) is a seasoned pharmaceutical executive with extensive experience in commercial strategy and corporate affairs. She previously served as Executive Vice President of Commercial Strategy & Corporate Affairs at Novo Nordisk, where she played a key role in shaping the company's strategic direction and stakeholder engagement. With her deep expertise in the pharmaceutical industry, Camilla brings valuable insights in commercial operations, strategic planning, and corporate governance. She is committed to advancing healthcare innovation and fostering sustainable growth in the life sciences sector.

Pierre DETRIXHE is a Managing Partner at InvestSud. He brings over 15 years of experience in early-stage investments with a strong focus on deep tech and life sciences. He has overseen major exits including EsoBiotec (acquired for $1Bn), demonstrating a strong track record in scaling innovative biotech ventures and driving strategic value creation. His expertise spans venture capital, technology transfer, and EU-funded innovation programs, making him a key figure in high-growth technology investment.

Helene SABATEL is an investment Manager at Noshaq, with a strong background in life sciences technology transfer and IP strategy. At Noshaq, actively supports and scales life sciences ventures, contributing to recent successful exits such as Vésale Pharma (LBO by Ceres Pharma), Nucleis Radiopharmaceuticals (acquired by Curium Pharma), and GQ Biotherapeutics (acquired by Pacira Bioscience). She holds a PhD in biochemistry and expertise bridging deep science and venture capital.

Marie CHAMBODUT is a Managing Director at Angelor, with extensive experience in financial analysis, portfolio management, and private equity investments. She has driven Angelor’s recent investment in Dillico (AI-powered healthcare services) and actively contributed to strategic exits including Waga Energy (valued at €540M) and Sublimed (acquired by Laboratoires Expanscience). (With over a decade in asset management and venture capital, Marie specializes in scaling high-potential SMEs and life sciences ventures.

Loïc LUCEL is an Investment Officer at UI Investissement, with expertise in financial modeling and strategic analysis for growth-stage companies. He has contributed to high-value transactions, including the $1.02Bn exit of Amolyt. Loïc brings extensive experience from roles in market research, analytics, and private equity, supporting the scaling of innovative businesses.

Laurent SACCUCCI is an Investment Director at Crédit Agricole Création, with strong expertise in pharma and biotech venture financing. Laurent played a key role in the $350M exit of Mablink, showcasing his experience in supporting innovative therapeutics and scaling high-potential life sciences companies.

Dr. François Ghiringhelli, (MD, PhD), head of the scientific board of Brenus Pharma. He is also director of the translational research center for molecular medicine at the Georges-François Leclerc Center in Dijon. Dr. Ghiringhelli is a leading expert in molecular medicine and translational research. He was recently named a laureate for the second time by the Amgen France Fund for Science and Humanity, recognizing his exceptional contributions to the field.

Pr Olivera J. Finn, (PhD) is a distinguished professor in the department of immunology, at the university of Pittsburgh School of Medicine. Dr. Finn is a pioneer in cancer immunology, known for her groundbreaking work on tumor antigens and preventive cancer vaccines. Former president of the American Association of Immunologists, she has received prestigious honors such as the AAI Lifetime Achievement Award, the AACR Lloyd Old Cancer Immunology Prize, and the SITC Richard V. Smalley Memorial Award.

Dr Mark Yarchoan, (MD) is an assistant professor of oncology, and a liver cancer specialist at Johns Hopkins Hospital, in Baltimore, where he leads research on cancer immunotherapies and co-directs the Liver Cancer Clinic. He has received honors such as the ASCO young investigator award and the Cholangiocarcinoma Foundation’s Mark R. Clements Award.

Dr Ignacio Melero, (MD, PhD) is co-director of the department of immunology and immunotherapy, at CIMA, University of Navarra. Renowned immunologist with international experience in translational research he has held roles at Bristol Myers Squibb in the U.S. He is a key expert in cancer immunotherapy and immune mechanisms.

Pr Julien Taieb (MD, PhD) is professor at Université de Paris, head of gastroenterology and GI Oncology at Georges Pompidou Hospital. Pr. Taieb is a renowned expert in gastrointestinal oncology, particularly in colorectal and pancreatic cancers. He has led over 10 national and international Phase II/III trials and authored more than 400 scientific publications. Active in ESMO and ASCO, he also sits on the editorial board of ESMO GI Oncology, driving innovation through clinical and translational research.

Pr Ahmad Awada (MD, PhD) is head of oncology department & director at the Chirec Cancer Institute, Brussels. Internationally recognized for his expertise in breast cancer, Pr. Awada has over 35 years of experience in oncology. He plays a key role in major societies like ASCO, ESMO, and EORTC, driving innovation in cancer treatment and research.

‍

Pr Antoine Italiano (MD, PhD) is head of early phase trials unit, at Institut Bergonié in Bordeaux, and head of precision medicine, at Gustave Roussy Cancer Institutue in Paris. Internationally recognized for his work on sarcomas and rare cancers, Pr. Italiano leads early-phase research and precision medicine initiatives. Author of 400+ publications, he is among the most cited oncology researchers.

is anexperienced business leaderwith a strong track record in thepharmaceutical industry.He is currently the GeneralManager of CSL Vifor and waspreviously the President ofLEEM (French PharmaAssociation) and CEO of GSKFrance.He has a wealth of knowledgeand experience in the field, andis committed to drivinginnovation and growth in theindustry.

(PharmD) is a highly experienced healthcare professional with over 20 years of experience in the field. He currently serves as an Administrator for Angels Santé and a Board Member for the French Society of Predictive & Personalized Medicine (SFMPP). Prior to this, he was the Head of Strategy & Therapeutic units at Roche France. Stéphane is committed to improving patient outcomes through healthcare innovation.

‍

(PharmD, LL.M, MBA) is currently the CEO of MRGN Advisors, Executive VP of CanSino Biologics, Regional partners at Mérieux Equity Partners; Board Chairman and Non-Executive Director at Univercells. He has a strong background in the pharmaceutical and biotechnology industries, with expertise in business development, strategic planning, and regulatory affairs.